IL17A and psoriasis vulgaris: Both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) have approved different monoclonal antibodies (mAbs) for treating plaque psoriasis, targeting TNF-α (e.g., adalimumab, etanercept, infliximab) [25,26], IL-23 (e.g., risankizumab, tildrakizumab, guselkumab) [27,28], and IL-17 (e.g., secukinumab, brodalumab, bimekizumab, ixekinumab) [14,23,29].